Login
Sign Up
Login
Sign Up
Features
Pricing
Reg.News
Contact
Login
Sign Up
Search
Providers
Companies
⨯
LIVE
Event in Progress:
Join Here
×
Search
Providers
Companies
⨯
Features
Pricing
Event Hub
Reg.News
Short Interest
Contact
All the news articles and press releases in one place.
UK Reg. News
German Reg. News
Search
Key Announcements
Results / Trading Updates
Get free RNS email alerts for@Model.CurrentFilterValue
Currently filtered for SANOFI
Clear Filter
Sector
Automobile Industry
Banks
Basic Materials
Building & Construction
Chemicals
Consumer Discretionary Goods
Consumer Discretionary Services
Consumer Staple Goods
Consumer Staple Services
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Finance
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Market Cap
Below £20m
£20m - £100m
£100m - £300m
£300m - £1bn
£1bn - £10bn
Over £10bn
Filters »
All
UK100
UK250
UK SmallCap
UK Other
Show:
10
25
50
100
«
1
»
Date / Time
Source
Ticker
Company
Sector
Market Cap
Announcement
02Dec22 11:15
RNS
SAN:PAR, 0A2V:LON
Sanofi, Sanofi Sponsored ADR
Various
Various
Citigroup Global Mkt - Form 38.5(a) (EPTRI) -Sanofi
02Dec22 11:13
RNS
SAN:PAR, 0A2V:LON
Sanofi, Sanofi Sponsored ADR
Various
Various
Citigroup Glbl Mkt E - Form 38.5 (b) (EPT/NON-RI)
06May21 06:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
30Apr21 16:56
GNW
0O59:LON
Sanofi
Health
0m
Annual General Meeting of April 30, 2021
28Apr21 06:30
GNW
0O59:LON
Sanofi
Health
0m
Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
26Apr21 07:00
GNW
0O59:LON
Sanofi
Health
0m
Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
23Apr21 15:05
GNW
0O59:LON
Sanofi
Health
0m
New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
19Apr21 06:00
GNW
0O59:LON
Sanofi
Health
0m
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
12Apr21 06:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
09Apr21 18:45
GNW
0O59:LON
Sanofi
Health
0m
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
09Apr21 05:01
GNW
0O59:LON
Sanofi
Health
0m
Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2
07Apr21 08:03
GNW
0O59:LON
Sanofi
Health
0m
Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
31Mar21 22:15
GNW
0O59:LON
Sanofi
Health
0m
FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
31Mar21 15:05
GNW
0O59:LON
Sanofi
Health
0m
Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine
19Mar21 06:30
GNW
0O59:LON
Sanofi
Health
0m
Availability of the Q1 2021 Memorandum for modelling purposes
15Mar21 06:00
GNW
0O59:LON
Sanofi
Health
0m
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival
12Mar21 06:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
04Mar21 17:18
GNW
0O59:LON
Sanofi
Health
0m
Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
04Mar21 06:00
GNW
0O59:LON
Sanofi
Health
0m
FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
03Mar21 17:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
22Feb21 18:00
GNW
0O59:LON
Sanofi
Health
0m
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
22Feb21 10:40
GNW
0O59:LON
Sanofi
Health
0m
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
12Feb21 06:00
GNW
0O59:LON
Sanofi
Health
0m
The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
09Feb21 22:15
GNW
0O59:LON
Sanofi
Health
0m
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
05Feb21 06:30
GNW
0O59:LON
Sanofi
Health
0m
Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
05Feb21 06:30
GNW
0O59:LON
Sanofi
Health
0m
Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
12Jan21 13:30
GNW
0O59:LON
Sanofi
Health
0m
SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer
11Jan21 07:30
GNW
0O59:LON
Sanofi
Health
0m
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
17Dec20 21:30
GNW
0O59:LON
Sanofi
Health
0m
Availability of the Q4 2020 Memorandum for modelling purposes
15Dec20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030
11Dec20 13:30
GNW
0O59:LON
Sanofi
Health
0m
CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes
11Dec20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
09Dec20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities
30Nov20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
23Nov20 09:00
GNW
0O59:LON
Sanofi
Health
0m
European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
18Nov20 18:12
GNW
0O59:LON
Sanofi
Health
0m
European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
18Nov20 06:15
GNW
0O59:LON
Sanofi
Health
0m
Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia
18Nov20 06:00
GNW
0O59:LON
Sanofi
Health
0m
FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
14Nov20 00:00
GNW
0O59:LON
Sanofi
Health
0m
FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
02Nov20 06:15
GNW
0O59:LON
Sanofi
Health
0m
Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
29Oct20 13:50
GNW
0O59:LON
Sanofi
Health
0m
European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)
29Oct20 06:30
GNW
0O59:LON
Sanofi
Health
0m
Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
29Oct20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology
28Oct20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
26Oct20 12:00
GNW
0O59:LON
Sanofi
Health
0m
Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
16Oct20 13:00
GNW
0O59:LON
Sanofi
Health
0m
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
15Oct20 13:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
13Oct20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
02Oct20 06:00
GNW
0O59:LON
Sanofi
Health
0m
EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
28Sep20 14:30
GNW
0O59:LON
Sanofi
Health
0m
Sanofi completes Principia Biopharma Inc. acquisition
25Sep20 06:30
GNW
0O59:LON
Sanofi
Health
0m
Availability of the Q3 2020 Memorandum for modelling purposes
22Sep20 17:30
GNW
0O59:LON
Sanofi
Health
0m
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
22Sep20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.
21Sep20 13:25
GNW
0O59:LON
Sanofi
Health
0m
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
21Sep20 01:25
GNW
0O59:LON
Sanofi
Health
0m
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
18Sep20 08:05
GNW
0O59:LON
Sanofi
Health
0m
Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO
18Sep20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation
14Sep20 06:00
GNW
0O59:LON
Sanofi
Health
0m
FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
10Sep20 06:00
GNW
0O59:LON
Sanofi
Health
0m
New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A
08Sep20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma
03Sep20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
01Sep20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.
28Aug20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.
17Aug20 06:00
GNW
0O59:LON
Sanofi
Health
0m
Sanofi to acquire Principia Biopharma
«
1
»
Date / Time
Source
Company
% Chg
02Dec22 11:15
RNS
Sanofi, Sanofi Sponsored ADR
0.00%
Citigroup Global Mkt - Form 38.5(a) (EPTRI) -Sanofi
02Dec22 11:13
RNS
Sanofi, Sanofi Sponsored ADR
0.00%
Citigroup Glbl Mkt E - Form 38.5 (b) (EPT/NON-RI)
06May21 06:00
GNW
Sanofi
0.00%
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
30Apr21 16:56
GNW
Sanofi
0.00%
Annual General Meeting of April 30, 2021
28Apr21 06:30
GNW
Sanofi
0.00%
Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
26Apr21 07:00
GNW
Sanofi
0.00%
Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
23Apr21 15:05
GNW
Sanofi
0.00%
New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
19Apr21 06:00
GNW
Sanofi
0.00%
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
12Apr21 06:00
GNW
Sanofi
0.00%
Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
09Apr21 18:45
GNW
Sanofi
0.00%
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
09Apr21 05:01
GNW
Sanofi
0.00%
Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2
07Apr21 08:03
GNW
Sanofi
0.00%
Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
31Mar21 22:15
GNW
Sanofi
0.00%
FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
31Mar21 15:05
GNW
Sanofi
0.00%
Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine
19Mar21 06:30
GNW
Sanofi
0.00%
Availability of the Q1 2021 Memorandum for modelling purposes
15Mar21 06:00
GNW
Sanofi
0.00%
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival
12Mar21 06:00
GNW
Sanofi
0.00%
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
04Mar21 17:18
GNW
Sanofi
0.00%
Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
04Mar21 06:00
GNW
Sanofi
0.00%
FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
03Mar21 17:00
GNW
Sanofi
0.00%
Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
22Feb21 18:00
GNW
Sanofi
0.00%
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
22Feb21 10:40
GNW
Sanofi
0.00%
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
12Feb21 06:00
GNW
Sanofi
0.00%
The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
09Feb21 22:15
GNW
Sanofi
0.00%
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
05Feb21 06:30
GNW
Sanofi
0.00%
Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
05Feb21 06:30
GNW
Sanofi
0.00%
Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
12Jan21 13:30
GNW
Sanofi
0.00%
SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer
11Jan21 07:30
GNW
Sanofi
0.00%
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
17Dec20 21:30
GNW
Sanofi
0.00%
Availability of the Q4 2020 Memorandum for modelling purposes
15Dec20 06:00
GNW
Sanofi
0.00%
Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030
11Dec20 13:30
GNW
Sanofi
0.00%
CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes
11Dec20 06:00
GNW
Sanofi
0.00%
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
09Dec20 06:00
GNW
Sanofi
0.00%
Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities
30Nov20 06:00
GNW
Sanofi
0.00%
Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
23Nov20 09:00
GNW
Sanofi
0.00%
European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
18Nov20 18:12
GNW
Sanofi
0.00%
European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
18Nov20 06:15
GNW
Sanofi
0.00%
Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia
18Nov20 06:00
GNW
Sanofi
0.00%
FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
14Nov20 00:00
GNW
Sanofi
0.00%
FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
02Nov20 06:15
GNW
Sanofi
0.00%
Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
29Oct20 13:50
GNW
Sanofi
0.00%
European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)
29Oct20 06:30
GNW
Sanofi
0.00%
Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
29Oct20 06:00
GNW
Sanofi
0.00%
Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology
28Oct20 06:00
GNW
Sanofi
0.00%
Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
26Oct20 12:00
GNW
Sanofi
0.00%
Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
16Oct20 13:00
GNW
Sanofi
0.00%
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
15Oct20 13:00
GNW
Sanofi
0.00%
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
13Oct20 06:00
GNW
Sanofi
0.00%
Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
02Oct20 06:00
GNW
Sanofi
0.00%
EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
28Sep20 14:30
GNW
Sanofi
0.00%
Sanofi completes Principia Biopharma Inc. acquisition
25Sep20 06:30
GNW
Sanofi
0.00%
Availability of the Q3 2020 Memorandum for modelling purposes
22Sep20 17:30
GNW
Sanofi
0.00%
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
22Sep20 06:00
GNW
Sanofi
0.00%
Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.
21Sep20 13:25
GNW
Sanofi
0.00%
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
21Sep20 01:25
GNW
Sanofi
0.00%
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
18Sep20 08:05
GNW
Sanofi
0.00%
Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO
18Sep20 06:00
GNW
Sanofi
0.00%
Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation
14Sep20 06:00
GNW
Sanofi
0.00%
FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
10Sep20 06:00
GNW
Sanofi
0.00%
New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A
08Sep20 06:00
GNW
Sanofi
0.00%
Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma
03Sep20 06:00
GNW
Sanofi
0.00%
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
01Sep20 06:00
GNW
Sanofi
0.00%
Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.
28Aug20 06:00
GNW
Sanofi
0.00%
Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.
17Aug20 06:00
GNW
Sanofi
0.00%
Sanofi to acquire Principia Biopharma
«
1
»
Date / Time
Company
% Chg
02Dec22 11:15
0A2V LSE,SNY NASDAQ-NMS,SAN EuronextParis,O.003562064 ORBISID,O.050247077 ORBISID,O.372678613 ORBISID
0.00%
Citigroup Global Mkt - Form 38.5(a) (EPTRI) -Sanofi
02Dec22 11:13
0A2V LSE,SNY NASDAQ-NMS,SAN EuronextParis,O.003562064 ORBISID,O.000754667 ORBISID,O.372678613 ORBISID
0.00%
Citigroup Glbl Mkt E - Form 38.5 (b) (EPT/NON-RI)
06May21 06:00
Sanofi
0.00%
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
30Apr21 16:56
Sanofi
0.00%
Annual General Meeting of April 30, 2021
28Apr21 06:30
Sanofi
0.00%
Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
26Apr21 07:00
Sanofi
0.00%
Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
23Apr21 15:05
Sanofi
0.00%
New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
19Apr21 06:00
Sanofi
0.00%
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
12Apr21 06:00
Sanofi
0.00%
Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
09Apr21 18:45
Sanofi
0.00%
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
09Apr21 05:01
Sanofi
0.00%
Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2
07Apr21 08:03
Sanofi
0.00%
Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
31Mar21 22:15
Sanofi
0.00%
FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
31Mar21 15:05
Sanofi
0.00%
Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine
19Mar21 06:30
Sanofi
0.00%
Availability of the Q1 2021 Memorandum for modelling purposes
15Mar21 06:00
Sanofi
0.00%
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival
12Mar21 06:00
Sanofi
0.00%
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
04Mar21 17:18
Sanofi
0.00%
Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
04Mar21 06:00
Sanofi
0.00%
FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
03Mar21 17:00
Sanofi
0.00%
Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
22Feb21 18:00
Sanofi
0.00%
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
22Feb21 10:40
Sanofi
0.00%
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
12Feb21 06:00
Sanofi
0.00%
The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
09Feb21 22:15
Sanofi
0.00%
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
05Feb21 06:30
Sanofi
0.00%
Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
05Feb21 06:30
Sanofi
0.00%
Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
12Jan21 13:30
Sanofi
0.00%
SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer
11Jan21 07:30
Sanofi
0.00%
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
17Dec20 21:30
Sanofi
0.00%
Availability of the Q4 2020 Memorandum for modelling purposes
15Dec20 06:00
Sanofi
0.00%
Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030
11Dec20 13:30
Sanofi
0.00%
CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes
11Dec20 06:00
Sanofi
0.00%
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
09Dec20 06:00
Sanofi
0.00%
Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities
30Nov20 06:00
Sanofi
0.00%
Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
23Nov20 09:00
Sanofi
0.00%
European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
18Nov20 18:12
Sanofi
0.00%
European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
18Nov20 06:15
Sanofi
0.00%
Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia
18Nov20 06:00
Sanofi
0.00%
FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
14Nov20 00:00
Sanofi
0.00%
FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
02Nov20 06:15
Sanofi
0.00%
Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
29Oct20 13:50
Sanofi
0.00%
European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)
29Oct20 06:30
Sanofi
0.00%
Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
29Oct20 06:00
Sanofi
0.00%
Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology
28Oct20 06:00
Sanofi
0.00%
Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
26Oct20 12:00
Sanofi
0.00%
Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
16Oct20 13:00
Sanofi
0.00%
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
15Oct20 13:00
Sanofi
0.00%
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
13Oct20 06:00
Sanofi
0.00%
Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
02Oct20 06:00
Sanofi
0.00%
EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
28Sep20 14:30
Sanofi
0.00%
Sanofi completes Principia Biopharma Inc. acquisition
25Sep20 06:30
Sanofi
0.00%
Availability of the Q3 2020 Memorandum for modelling purposes
22Sep20 17:30
Sanofi
0.00%
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
22Sep20 06:00
Sanofi
0.00%
Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.
21Sep20 13:25
Sanofi
0.00%
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
21Sep20 01:25
Sanofi
0.00%
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
18Sep20 08:05
Sanofi
0.00%
Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO
18Sep20 06:00
Sanofi
0.00%
Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation
14Sep20 06:00
Sanofi
0.00%
FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
10Sep20 06:00
Sanofi
0.00%
New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A
08Sep20 06:00
Sanofi
0.00%
Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma
03Sep20 06:00
Sanofi
0.00%
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
01Sep20 06:00
Sanofi
0.00%
Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.
28Aug20 06:00
Sanofi
0.00%
Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.
17Aug20 06:00
Sanofi
0.00%
Sanofi to acquire Principia Biopharma
«
1
»
Strapline
Strapline
Question 1
Answer 1
Question 2
Answer 2
Question 3
Answer 3
Question 4
Answer 4
Question 5
Answer 5
Question 6
Answer 6
Question 7
Answer 7
Question 8
Answer 8
Top
Home
Features
Pricing
Event Hub
Reg.News
Short Interest Tracker
Explore Content
Regions
UK
Rest of EMEA
N America
APAC
LatAm
Exchanges
Aquis Apex
Australian Securities Exchange
Canadian Securities Exchange
Euronext Paris
London Stock Exchange (domestic)
SIX Swiss Exchange
Sectors
Automobile Industry
Banks
Building & Construction
Chemicals
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Utilities
Small / Large Cap
UK100
UK250
UK Smallcap
UK Other Main Markets
Other
Private/EIS
EIS Single Company
EIS/SEIS Funds
IHT Products
SEIS Single Company
VCT Funds
Providers
Free/Commissioned
ACF Equity Research
Actio Advisors
Align Research
Atrium Research
BlytheRay
BNP Paribas Exane - Sponsored Research
Brand Communications
BRR Media
Calvine Partners
Capital Access Group
Capital Markets Brokers
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Edison
Equity Development
eResearch
Fidante Partners
Five Minute Pitch TV
focusIR
Fundamental Research Corp
Galliano’s Latin Notes
goetzpartners securities Limited
H2 Radnor
Hardman & Co
Holland Advisors
Hypothesis Research
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Magnitogorsk Iron and steel works
Mello Events
Mining Network
NuWays
Paul Scott
Peel Hunt
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Resolve Research
SEAL Advisors Ltd
ShareSoc
Shore Capital
Small Cap Consumer Research LLC
StockBox
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
Turner Pope Investments
UK Investor Group
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
High Net Worth Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane - Sponsored Research
Canaccord Genuity
Cavendish
Couloir Capital
Dowgate Capital
First Berlin
First Sentinel
GSBR Research
Hannam & Partners
Hybridan
Kemeny Capital
Liberum
Longspur Clean Energy
Louis Capital
Magnitogorsk Iron and steel works
Medley Global Advisors
Northland Capital Partners
QuotedData Professional
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
Tennyson Securities
The Life Sciences Division
Turner Pope Investments
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Institutional Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
BNP Paribas Exane
BRR Media
Calvine Partners
Canaccord Genuity
Capital Access Group
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Dowgate Capital
Edison
Equity Development
eResearch
Fidante Partners
First Berlin
First Sentinel
Five Minute Pitch TV
Fundamental Research Corp
Galliano’s Latin Notes
Goodbody
H2 Radnor
Hannam & Partners
Hardman & Co
Holland Advisors
Hybridan
Inbound Capital
Independent Investment Research
InterAxS Global
Investec Bank
Kemeny Capital
Kepler | Absolute Hedge
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Longspur Clean Energy
Magnitogorsk Iron and steel works
Mello Events
Mining Network
Northland Capital Partners
Numis
NuWays
Panmure Gordon
Peel Hunt
piworld.co.uk
Proactive
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
Small Cap Consumer Research LLC
SP Angel
Stanford Capital Partners
Stifel
StockBox
Tamesis Partners
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
UK Investor Group
Velocity Trade
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
Contact
Sign Up
Sign In
Share: